New Brunswick, NJNCT07354074Now EnrollingIRB Ready

Chronic Myelogenous Leukemia Clinical Trial in New Brunswick, NJ

Access cutting-edge chronic myelogenous leukemia treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access chronic myelogenous leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic myelogenous leukemia treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this chronic myelogenous leukemia clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This Chronic Myelogenous Leukemia Study in New Brunswick

The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Participants eligible for inclusion in this study must meet all of the following criteria:
Signed informed consent must be obtained prior to participation in the study.
Male or female participants 1 and \< 18 years of age at study enrollment
Diagnosis of CML-CP (Apperley et al 2025) with cytogenetic confirmation of Philadelphia positive (Ph+) chromosome
For participants with CML-CP newly diagnosed within 3 months of screening OR 5 For participants with CML - CP with high risk of developing resistance or intolerance to previous TKI:
Unfavourable response to TKI is defined following the Apperley et al 2025 guidelines as:
At three months after the initiation of therapy: BCR::ABL1 ratio \> 10% IS (if confirmed within 1-3 months)
At six months after the initiation of therapy: BCR::ABL1 ratio \> 10% IS
At twelve months after initiation of therapy: BCR::ABL1 ratio \> 1% IS
At any time loss of previous response
At any time emergent resistant BCR::ABL1 mutations or high-risk ACA from prior TKI treatment as per local test results
Intolerance to TKI is defined as:
Non-hematologic intolerance: participants with grade 3 or 4 toxicity while on therapy (in which case the patient is eligible whether or not there was a dose reduction); or with persistent grade 2 toxicity unresponsive to optimal management including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)
Hematologic intolerance: participants with grade 3 or 4 toxicity (absolute neutrophil count \[ANC\] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses of the TKI 6\. Evidence of typical BCR::ABL1 transcript \[e14a2 and/or e13a2\] at the time of screening which are amenable to standardized RQ-PCR quantification. 7\. Performance status: Karnofsky ≥ 50% for participants ≥ 16 years of age, and Lansky ≥ 50 for participants \< 16 years of age at the time of screening. Key

Exclusion Criteria

Known second chronic phase (CP) of CML after previous progression to Accelerated Phase (AP)/Blast Phase (BP).
Previous treatment with a hematopoietic stem-cell transplantation.
Patient planned to undergo allogeneic hematopoietic stem cell transplantation
Known presence of a BCR::ABL1 mutation with known resistance to study treatment in accordance with the most recent public version of international CML clinical guidelines (e.g. NCCN CML treatment guidelines v 1.2026 and Apperley et al 2025) any time prior to study entry Other inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT07354074) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Myelogenous Leukemia Treatment Options in New Brunswick, NJ

If you're searching for chronic myelogenous leukemia treatment options in New Brunswick, NJ, this clinical trial (NCT07354074) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic myelogenous leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic myelogenous leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in New Brunswick, NJ

See all leukemia clinical trials recruiting in New Brunswick — not just this study.

Browse Leukemia Trials in New Brunswick →

Browse More Trials by Condition

Leukemia TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsChronic Myeloid Leukemia TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ